

Prospective evaluation of methylated *SEPT9* in plasma of colorectal cancer

Gut

63, 317-325

DOI: [10.1136/gutjnl-2012-304149](https://doi.org/10.1136/gutjnl-2012-304149)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Molecular biomarkers in esophageal, gastric, and colorectal adenocarcinoma. , 2013, 140, 133-147.		27
2	Methylated DNA and microRNA in Body Fluids as Biomarkers for Cancer Detection. International Journal of Molecular Sciences, 2013, 14, 10307-10331.	1.8	37
3	Clinical application of the CpG island methylator phenotype to prognostic diagnosis in neuroblastomas. Journal of Human Genetics, 2013, 58, 428-433.	1.1	20
4	Diagnostic and Prognostic Value of SHOX2 and SEPT9 DNA Methylation and Cytology in Benign, Paramalignant and Malignant Pleural Effusions. PLoS ONE, 2013, 8, e84225.	1.1	68
5	Performance Evaluation of Kits for Bisulfite-Conversion of DNA from Tissues, Cell Lines, FFPE Tissues, Aspirates, Lavages, Effusions, Plasma, Serum, and Urine. PLoS ONE, 2014, 9, e93933.	1.1	110
6	Plasma Septin9 versus Fecal Immunochemical Testing for Colorectal Cancer Screening: A Prospective Multicenter Study. PLoS ONE, 2014, 9, e98238.	1.1	134
7	Colorectal cancer: From prevention to personalized medicine. World Journal of Gastroenterology, 2014, 20, 6786.	1.4	281
9	Colorectal cancer: screening and some notes on the prevention. Memo - Magazine of European Medical Oncology, 2014, 7, 187-191.	0.3	0
10	Detection of colorectal cancer by DNA methylation biomarker SEPT9: past, present and future. Biomarkers in Medicine, 2014, 8, 755-769.	0.6	33
11	Cancer diagnostic classifiers based on quantitative DNA methylation. Expert Review of Molecular Diagnostics, 2014, 14, 293-305.	1.5	59
12	Cost-effectiveness of colorectal cancer screening in Germany: current endoscopic and fecal testing strategies versus plasma methylated Septin 9 DNA. Endoscopy International Open, 2014, 02, E96-E104.	0.9	42
13	A novel gene expression signature in peripheral blood mononuclear cells for early detection of colorectal cancer. Alimentary Pharmacology and Therapeutics, 2014, 39, 507-517.	1.9	21
14	Cancer-associated autoantibodies to MUC1 and MUC4 – A blinded case-control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. International Journal of Cancer, 2014, 134, 2180-2188.	2.3	49
15	Aberrant promoter methylation of <i>PPP1R3C</i> and <i>EFHD1</i> in plasma of colorectal cancer patients. Cancer Medicine, 2014, 3, 1235-1245.	1.3	40
16	Proteomics, genomics and transcriptomics: their emerging roles in the discovery and validation of colorectal cancer biomarkers. Expert Review of Proteomics, 2014, 11, 179-205.	1.3	31
17	Two-stage Genome-wide Methylation Profiling in Childhood-onset Crohn's Disease Implicates Epigenetic Alterations at the VMP1/MIR21 and HLA Loci. Inflammatory Bowel Diseases, 2014, 20, 1784-1793.	0.9	84
18	Controversies in Colorectal Cancer Screening. Digestion, 2014, 89, 274-281.	1.2	34
19	DNA methylome profiling identifies novel methylated genes in African American patients with colorectal neoplasia. Epigenetics, 2014, 9, 503-512.	1.3	70

#	ARTICLE	IF	CITATIONS
20	Epigenetic therapies - a new direction in clinical medicine. <i>International Journal of Clinical Practice</i> , 2014, 68, 802-811.	0.8	11
21	Biomarker research with prospective study designs for the early detection of cancer. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2014, 1844, 874-883.	1.1	41
22	Long-acting HIV drugs advanced to overcome adherence challenge. <i>Nature Medicine</i> , 2014, 20, 323-324.	15.2	48
23	DNA Methylation and Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 425-430.	1.0	46
24	Colorectal cancer screening: will non-invasive procedures triumph?. <i>Genome Medicine</i> , 2014, 6, 125.	3.6	4
25	Nucleic acid-based tissue biomarkers of urologic malignancies. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014, 51, 173-199.	2.7	33
26	DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer. <i>Biochemical and Biophysical Research Communications</i> , 2014, 455, 43-57.	1.0	139
27	Epigenetic epidemiology of cancer. <i>Biochemical and Biophysical Research Communications</i> , 2014, 455, 70-83.	1.0	88
28	Validation of a Real-Time PCR-Based Qualitative Assay for the Detection of Methylated SEPT9 DNA in Human Plasma. <i>Clinical Chemistry</i> , 2014, 60, 1183-1191.	1.5	210
29	To foster screening, new colon cancer tests emphasize convenience. <i>Nature Medicine</i> , 2014, 20, 322-323.	15.2	2
30	Tests and investigations for colorectal cancer screening. <i>Clinical Biochemistry</i> , 2014, 47, 921-939.	0.8	77
31	Endoscopic Detection of Proximal Serrated Lesions and Pathologic Identification of Sessile Serrated Adenomas/Polyps Vary on the Basis of Center. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1119-1126.	2.4	137
32	Blood-Based Testing for Colorectal Cancer Screening. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 127-135.	1.6	21
33	Colorectal cancer biomarkers: To be or not to be? Cautionary tales from a road well travelled. <i>World Journal of Gastroenterology</i> , 2014, 20, 888.	1.4	21
34	SEPT9. <i>Advances in Clinical Chemistry</i> , 2015, 72, 171-204.	1.8	62
35	DNA methylation signatures in circulating cell-free DNA for the monitoring of at-risk populations progressing to lung cancer. <i>EBioMedicine</i> , 2015, 2, 798-799.	2.7	7
36	Colorectal cancer. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15065.	18.1	1,104
37	Blood-based Biomarkers at Large Bowel Endoscopy and Prediction of Future Malignancies. <i>Biomarkers in Cancer</i> , 2015, 7, BIC.S31330.	3.6	7

#	ARTICLE	IF	CITATIONS
38	Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested caseâ€“control study. <i>BMC Cancer</i> , 2015, 15, 819.	1.1	39
39	Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia. <i>BMC Cancer</i> , 2015, 15, 654.	1.1	96
40	Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue. <i>Prostate</i> , 2015, 75, 1941-1950.	1.2	44
41	Noninvasive DNA methylation biomarkers in colorectal cancer: A systematic review. <i>Journal of Digestive Diseases</i> , 2015, 16, 699-712.	0.7	18
42	Analysis of 32 Blood-Based Protein Biomarkers for their Potential to Diagnose Colorectal Cancer. <i>Journal of Molecular Biomarkers & Diagnosis</i> , 2015, s6, .	0.4	0
43	A Two-Gene Blood Test for Methylated DNA Sensitive for Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0125041.	1.1	59
44	Colorectal cancer screening: a global overview of existing programmes. <i>Gut</i> , 2015, 64, 1637-1649.	6.1	899
45	Colorectal Carcinoma: What Should the Oncologist Recommend for Screening?. <i>Seminars in Oncology</i> , 2015, 42, 359-361.	0.8	0
46	Molecular markers for colorectal cancer screening. <i>Gut</i> , 2015, 64, 1485-1494.	6.1	100
47	Head-to-Head Comparison and Evaluation of 92 Plasma Protein Biomarkers for Early Detection of Colorectal Cancer in a True Screening Setting. <i>Clinical Cancer Research</i> , 2015, 21, 3318-3326.	3.2	39
48	Blood Tests for Colorectal Cancer Screening in the Standard Risk Population. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 397-407.	1.0	7
49	Performance of a secondâ€“generation methylated <scp>SEPT9</scp> test in detecting colorectal neoplasm. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 830-833.	1.4	115
50	Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma. <i>Hepatology</i> , 2015, 61, 1651-1659.	3.6	94
51	Plasma methylated septin 9: a colorectal cancer screening marker. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 171-184.	1.5	45
53	Faecal Occult Blood Testing for Colorectal Cancer Screening: the Past or the Future. <i>Current Gastroenterology Reports</i> , 2015, 17, 428.	1.1	13
55	Blood-Based Tests for Colorectal Cancer Screening: Do They Threaten the Survival of the FIT Test?. <i>Digestive Diseases and Sciences</i> , 2015, 60, 664-671.	1.1	38
56	The effect of colonoscopy on whole blood gene expression profile: an experimental investigation for colorectal cancer biomarker discovery. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 591-599.	1.2	0
57	Epigenetic Alterations in Colorectal Cancer: EmergingÂ“Biomarkers. <i>Gastroenterology</i> , 2015, 149, 1204-1225.e12.	0.6	561

#	ARTICLE	IF	CITATIONS
58	Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. <i>British Journal of Cancer</i> , 2015, 113, 268-274.	2.9	84
59	Choosing the optimal method in programmatic colorectal cancer screening: current evidence and controversies. <i>Therapeutic Advances in Gastroenterology</i> , 2015, 8, 221-233.	1.4	15
60	Targeted deep DNA methylation analysis of circulating cell-free DNA in plasma using massively parallel semiconductor sequencing. <i>Epigenomics</i> , 2015, 7, 353-362.	1.0	36
61	Accuracy of Capsule Colonoscopy in Detecting Colorectal Polyps in a Screening Population. <i>Gastroenterology</i> , 2015, 148, 948-957.e2.	0.6	160
62	Do Circulating Tumor Cells, Exosomes, and Circulating Tumor Nucleic Acids Have Clinical Utility?. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 209-224.	1.2	176
64	Methylation of cell-free circulating DNA in the diagnosis of cancer. <i>Frontiers in Molecular Biosciences</i> , 2015, 2, 13.	1.6	159
66	Targeting cancer epigenetics: Linking basic biology to clinical medicine. <i>Advanced Drug Delivery Reviews</i> , 2015, 95, 56-64.	6.6	34
67	Non-invasive screening for colorectal cancer in Asia. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2015, 29, 953-965.	1.0	20
68	Rising incidence of early-onset colorectal cancer in Australia over two decades: Report and review. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 6-13.	1.4	119
69	MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas. <i>Cancer Prevention Research</i> , 2015, 8, 1112-1119.	0.7	25
71	Diagnostic and prognostic epigenetic biomarkers in cancer. <i>Epigenomics</i> , 2015, 7, 1003-1015.	1.0	173
72	Bisulfite Conversion of DNA from Tissues, Cell Lines, Buffy Coat, FFPE Tissues, Microdissected Cells, Swabs, Sputum, Aspirates, Lavages, Effusions, Plasma, Serum, and Urine. <i>Methods in Molecular Biology</i> , 2015, 1589, 139-159.	0.4	17
73	Liquid biopsy for cancer patients: Principles and practice. <i>Pathogenesis</i> , 2015, 2, 1-4.	0.8	31
74	The value of models in informing resource allocation in colorectal cancer screening: the case of the Netherlands. <i>Gut</i> , 2015, 64, 1985-1997.	6.1	58
75	Multi-Target Stool DNA Test: A New High Bar for Noninvasive Screening. <i>Digestive Diseases and Sciences</i> , 2015, 60, 623-633.	1.1	57
76	Circulating Tumor DNA as a Liquid Biopsy for Cancer. <i>Clinical Chemistry</i> , 2015, 61, 112-123.	1.5	654
77	Colorectal cancer in the young, many questions, few answers. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 481.	0.8	55
78	Genomics of Colorectal Cancer in African Americans. <i>Journal of Next Generation Sequencing & Applications</i> , 2016, 3, .	0.3	9

#	ARTICLE	IF	CITATIONS
79	Use of Chromatin Changes as Biomarkers. , 2016, , 403-421.		0
80	Discovery and Validation of Plasma-Protein Biomarker Panels for the Detection of Colorectal Cancer and Advanced Adenoma in a Danish Collection of Samples from Patients Referred for Diagnostic Colonoscopy. <i>Journal of Applied Laboratory Medicine</i> , 2016, 1, 181-193.	0.6	7
81	Diagnostic Value of Methylated Septin9 for Colorectal Cancer Screening: A Meta-Analysis. <i>Medical Science Monitor</i> , 2016, 22, 3409-3418.	0.5	23
82	Colorectal Cancer Screening in Average Risk Populations: Evidence Summary. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-18.	0.8	37
83	The Emergence of Pan-Cancer CIMP and Its Elusive Interpretation. <i>Biomolecules</i> , 2016, 6, 45.	1.8	22
84	Liquid biopsies: tumour diagnosis and treatment monitoring. <i>Biomedical Research and Therapy</i> , 2016, 3, .	0.3	1
85	Role of Urinary Biomarkers in the Diagnosis of Adenoma and Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Cancer</i> , 2016, 7, 1984-2004.	1.2	26
86	<i>PD-L1</i> promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. <i>Oncotarget</i> , 2016, 7, 79943-79955.	0.8	73
87	Cell-free DNA as a diagnostic marker for cancer: current insights. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6549-6559.	1.0	104
88	Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting. <i>Oncotarget</i> , 2016, 7, 16420-16432.	0.8	42
89	Colorectal Cancer Screening: Stool DNA and Other Noninvasive Modalities. <i>Gut and Liver</i> , 2016, 10, 204.	1.4	53
90	Hypermethylated DNA as a biomarker for colorectal cancer: a systematic review. <i>Colorectal Disease</i> , 2016, 18, 549-561.	0.7	60
91	Predicting advanced neoplasia at colonoscopy in a diverse population with the National Cancer Institute colorectal cancer risk assessment tool. <i>Cancer</i> , 2016, 122, 2663-2670.	2.0	25
92	Use of NCCN Guidelines, Other Guidelines, and Biomarkers for Colorectal Cancer Screening. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1479-1485.	2.3	21
93	Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract. <i>Clinical Epigenetics</i> , 2016, 8, 133.	1.8	38
94	SEPT9 and SHOX2 DNA methylation status and its utility in the diagnosis of colonic adenomas and colorectal adenocarcinomas. <i>Clinical Epigenetics</i> , 2016, 8, 100.	1.8	46
95	Evaluation of serum nucleoside diphosphate kinase A for the detection of colorectal cancer. <i>Scientific Reports</i> , 2016, 6, 26703.	1.6	12
96	Detection of Colorectal Cancer Using a Simplified SEPT9 Gene Methylation Assay Is a Reliable Method for Opportunistic Screening. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 535-545.	1.2	91

#	ARTICLE	IF	CITATIONS
97	Methylated DNA as Cancer Biomarkers in Circulation. , 2016, , 103-123.		1
99	Methylation of the SEPT9_v2 promoter as a novel marker for the detection of circulating tumor DNA in breast cancer patients. <i>Oncology Reports</i> , 2016, 36, 2225-2235.	1.2	27
100	Current status and future perspectives of circulating cell-free DNA methylation in clinical diagnostics. <i>Laboratoriums Medizin</i> , 2016, 40, 335-343.	0.1	3
101	Diagnostics and Epidemiology of Colorectal Cancer. <i>Visceral Medicine</i> , 2016, 32, 158-164.	0.5	144
102	Development and validation of a multiplex methylation specific PCR-coupled liquid bead array for liquid biopsy analysis. <i>Clinica Chimica Acta</i> , 2016, 461, 156-164.	0.5	10
103	Cancer Biomarkers in Body Fluids. , 2016, , .		5
104	Detection of Methylated DNA on a Power-Free Microfluidic Chip with Laminar Flow-Assisted Dendritic Amplification. <i>Analytical Sciences</i> , 2016, 32, 603-606.	0.8	22
105	Detection of aberrant methylated SEPT9 and NTRK3 genes in sporadic colorectal cancer patients as a potential diagnostic biomarker. <i>Oncology Letters</i> , 2016, 12, 5335-5343.	0.8	26
107	The Role of Stem Cell DNA Methylation in Colorectal Carcinogenesis. <i>Stem Cell Reviews and Reports</i> , 2016, 12, 573-583.	5.6	16
108	Current and Emerging Technologies for the Analysis of the Genome-Wide and Locus-Specific DNA Methylation Patterns. <i>Advances in Experimental Medicine and Biology</i> , 2016, 945, 343-430.	0.8	22
109	Colorectal Cancer Screening Recommendationsâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1717.	3.8	44
110	Molecular Biomarkers of Colorectal Cancer and Cancer Disparities: Current Status and Perspective. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 332-344.	1.0	18
111	Genome-wide DNA methylation analysis identifies candidate epigenetic markers and drivers of hepatocellular carcinoma. <i>Briefings in Bioinformatics</i> , 2018, 19, bbw094.	3.2	53
112	Molecular Diagnosis of Colorectal Cancer. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2016, 69, 480-488.	0.1	0
113	Emerging stool-based and blood-based non-invasive DNA tests for colorectal cancer screening: the importance of cancer prevention in addition to cancer detection. <i>Abdominal Radiology</i> , 2016, 41, 1441-1444.	1.0	41
114	Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites. <i>Clinical Epigenetics</i> , 2016, 8, 24.	1.8	31
115	Analysis of RET promoter CpG island methylation using methylation-specific PCR (MSP), pyrosequencing, and methylation-sensitive high-resolution melting (MS-HRM): impact on stage II colon cancer patient outcome. <i>Clinical Epigenetics</i> , 2016, 8, 44.	1.8	18
116	Blood-Based Screening for Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2519.	3.8	31

#	ARTICLE	IF	CITATIONS
117	Colorectal Cancer Screening. <i>JAMA Oncology</i> , 2016, 2, 1001.	3.4	1
118	Screening for Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2564.	3.8	1,725
119	Blood-based biomarkers for diagnosis, prognosis and treatment of colorectal cancer. <i>Clinica Chimica Acta</i> , 2016, 455, 26-32.	0.5	59
120	Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 239-252.	1.5	36
122	A Blood Test for Methylated BCAT1 and IKZF1 vs. a Fecal Immunochemical Test for Detection of Colorectal Neoplasia. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e137.	1.3	75
123	Post-Polypectomy Surveillance That Would Please Goldilocksâ€™Not Too Much, Not Too Little, but Just Right. <i>Gastroenterology</i> , 2016, 150, 791-796.	0.6	16
124	Evaluation of a 5-Marker Blood Test for Colorectal Cancer Early Detection in a Colorectal Cancer Screening Setting. <i>Clinical Cancer Research</i> , 2016, 22, 1725-1733.	3.2	53
125	The promise of omics-based approaches to cancer prevention. <i>Seminars in Oncology</i> , 2016, 43, 36-48.	0.8	10
126	CA11-19: a tumor marker for the detection of colorectal cancer. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 545-551.	0.5	12
127	A novel method for screening colorectal cancer by infrared spectroscopy of peripheral blood mononuclear cells and plasma. <i>Journal of Gastroenterology</i> , 2016, 51, 214-221.	2.3	22
128	Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer. <i>Gut</i> , 2016, 65, 990-1000.	6.1	67
129	Diagnostic Accuracy of Methylated SEPT9 for Blood-based Colorectal Cancer Detection: A Systematic Review and Meta-Analysis. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e216.	1.3	79
130	The clinical role of circulating free tumor DNA in gastrointestinal malignancy. <i>Translational Research</i> , 2017, 183, 137-154.	2.2	14
131	DNA methylation signatures in circulating cell-free DNA as biomarkers for the early detection of cancer. <i>Science China Life Sciences</i> , 2017, 60, 356-362.	2.3	25
132	CpG Methylation Signature Predicts Recurrence in Early-Stage Hepatocellular Carcinoma: Results From a Multicenter Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 734-742.	0.8	148
133	Screening for Colorectal Neoplasia. <i>New England Journal of Medicine</i> , 2017, 376, 149-156.	13.9	86
134	DNA Methylationâ€™Based Biomarkers. <i>Journal of Clinical Oncology</i> , 2017, 35, 793-795.	0.8	7
135	Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?. <i>European Journal of Surgical Oncology</i> , 2017, 43, 949-962.	0.5	38

#	ARTICLE	IF	CITATIONS
136	The performance of the mSEPT9 assay is influenced by algorithm, cancer stage and age, but not sex and cancer location. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1093-1101.	1.2	41
137	Screening for colorectal cancer. <i>Seminars in Oncology</i> , 2017, 44, 34-44.	0.8	33
138	Epigenome-wide discovery and evaluation of leukocyte DNA methylation markers for the detection of colorectal cancer in a screening setting. <i>Clinical Epigenetics</i> , 2017, 9, 24.	1.8	37
139	Epi proColon [®] 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 225-232.	1.6	148
140	Circulating Tumor DNA as Biomarkers for Cancer Detection. <i>Genomics, Proteomics and Bioinformatics</i> , 2017, 15, 59-72.	3.0	185
141	Identification of differentially expressed genes and their upstream regulators in colorectal cancer. <i>Cancer Gene Therapy</i> , 2017, 24, 244-250.	2.2	29
142	Future perspectives of circulating tumor DNA in colorectal cancer. <i>Tumor Biology</i> , 2017, 39, 101042831770574.	0.8	16
143	The <i>SEPT9</i> gene methylation assay is capable of detecting colorectal adenoma in opportunistic screening. <i>Epigenomics</i> , 2017, 9, 599-610.	1.0	37
144	A systematic review of the performance of the SEPT9 gene methylation assay in colorectal cancer screening, monitoring, diagnosis and prognosis. <i>Cancer Biomarkers</i> , 2017, 18, 425-432.	0.8	38
145	Screening for Thyroid Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1888.	3.8	500
146	Colorectal Cancer Biomarkers in Circulation. , 2017, , 213-246.		2
147	Progress on the clinical application of the <i>SEPT9</i> gene methylation assay in the past 5 years. <i>Biomarkers in Medicine</i> , 2017, 11, 415-418.	0.6	25
148	Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study. <i>Clinical Chemistry</i> , 2017, 63, 1288-1296.	1.5	97
149	Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. <i>Gastroenterology</i> , 2017, 153, 307-323.	0.6	512
150	Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. <i>American Journal of Gastroenterology</i> , 2017, 112, 1016-1030.	0.2	483
151	Early detection: the impact of genomics. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 165-173.	1.4	10
152	Genetic and epigenetic markers in colorectal cancer screening: recent advances. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 665-685.	1.5	22
155	Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients. <i>Pathology and Oncology Research</i> , 2017, 23, 699-706.	0.9	26

#	ARTICLE	IF	CITATIONS
156	Detection of colorectal neoplasia: Combination of eight blood-based, cancer-associated protein biomarkers. <i>International Journal of Cancer</i> , 2017, 140, 1436-1446.	2.3	37
157	Methylation of Septin9 mediated by DNMT3a enhances hepatic stellate cells activation and liver fibrogenesis. <i>Toxicology and Applied Pharmacology</i> , 2017, 315, 35-49.	1.3	45
158	Imaging and Screening for Colorectal Cancer with CT Colonography. <i>Radiologic Clinics of North America</i> , 2017, 55, 1183-1196.	0.9	33
159	Screening of colorectal cancer: present and future. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1131-1146.	1.1	123
160	Future Perspective of DNA and Histone Methylation as Cancer Targets. <i>Cancer Drug Discovery and Development</i> , 2017, , 607-622.	0.2	0
161	Epigenetics and Precision Oncology. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 262-269.	1.0	73
162	International variation in the prevalence of preclinical colorectal cancer: Implications for predictive values of noninvasive screening tests and potential target populations for screening. <i>International Journal of Cancer</i> , 2017, 141, 1566-1575.	2.3	3
163	Global perspective on colonoscopy use for colorectal cancer screening: A multi-country survey of practicing colonoscopists. <i>Contemporary Clinical Trials Communications</i> , 2017, 7, 116-121.	0.5	11
164	<i>TERT</i> Promoter Hypermethylation in Gastrointestinal Cancer: A Potential Stool Biomarker. <i>Oncologist</i> , 2017, 22, 1178-1188.	1.9	15
165	A pooled analysis of the diagnostic efficacy of plasmic methylated septin-9 as a novel biomarker for colorectal cancer. <i>Biomedical Reports</i> , 2017, 7, 353-360.	0.9	17
166	The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis. <i>Scientific Reports</i> , 2017, 7, 3032.	1.6	112
167	The role of neurotensin as a novel biomarker in the endoscopic screening of high-risk population for developing colorectal neoplasia. <i>Updates in Surgery</i> , 2017, 69, 397-402.	0.9	12
168	Colorectal cancer screening: Recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. <i>Gastrointestinal Endoscopy</i> , 2017, 86, 18-33.	0.5	145
169	Beyond Colonoscopy: The Role of Alternative Screening Tests for Colorectal Cancer in Your Practice. <i>American Journal of Gastroenterology</i> , 2017, 112, 8-10.	0.2	3
170	Validation of the SHOX2 / PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease. <i>Journal of Thoracic Oncology</i> , 2017, 12, 77-84.	0.5	122
171	The Relationship between the Methylated Septinâ€9 DNA Blood Test and Stool Occult Blood Test for Diagnosing Colorectal Cancer in Taiwanese People. <i>Journal of Clinical Laboratory Analysis</i> , 2017, 31, .	0.9	22
173	Stool- and Blood-Based Molecular Tests in Screening for Colorectal Cancer: Ready for Prime Time?. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 481-488.	1.0	0
175	Epigenetic Biomarkers. , 2017, , 277-292.		0

#	ARTICLE	IF	CITATIONS
176	Molecular Techniques for DNA Methylation Studies. , 2017, , 103-139.		5
177	Colorectal Cancer Blood-Based Biomarkers. Gastroenterology Research and Practice, 2017, 2017, 1-11.	0.7	39
178	Screening for Colorectal Cancer Based on the Promoter Methylation Status of the Septin 9 Gene in Plasma Cell Free DNA. Journal of Clinical Epigenetics, 2017, 03, .	0.3	4
179	Abnormal DNA methylation as a cell-free circulating DNA biomarker for colorectal cancer detection: A review of literature. World Journal of Gastrointestinal Oncology, 2017, 9, 142.	0.8	27
180	Hypermethylated DNA, a circulating biomarker for colorectal cancer detection. PLoS ONE, 2017, 12, e0180809.	1.1	62
181	The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review. BMC Cancer, 2017, 17, 697.	1.1	94
182	A long-range interactive DNA methylation marker panel for the promoters of HOXA9 and HOXA10 predicts survival in breast cancer patients. Clinical Epigenetics, 2017, 9, 73.	1.8	25
183	Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients. Clinical Epigenetics, 2017, 9, 125.	1.8	38
184	Development and validation of a panel of five proteins as blood biomarkers for early detection of colorectal cancer. Clinical Epidemiology, 2017, Volume 9, 517-526.	1.5	24
185	Colorectal cancer screening: An updated review of the available options. World Journal of Gastroenterology, 2017, 23, 5086.	1.4	405
186	Validation of a Circulating Tumor-Derived DNA Blood Test for Detection of Methylated <i>BCAT1</i> and <i>IKZF1</i> DNA. journal of applied laboratory medicine, The, 2017, 2, 165-175.	0.6	9
187	Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer. Oncotarget, 2017, 8, 55632-55645.	0.8	116
188	Review of Blood-Based Colorectal Cancer Screening: How Far Are Circulating Cell-Free DNA Methylation Markers From Clinical Implementation?. Clinical Colorectal Cancer, 2018, 17, e415-e433.	1.0	49
189	Bowel cancer screening for women at midlife. Climacteric, 2018, 21, 243-248.	1.1	0
190	Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. EBioMedicine, 2018, 30, 138-147.	2.7	116
191	Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia. International Journal of Cancer, 2018, 143, 269-282.	2.3	28
192	Fecal immunochemical tests in combination with blood tests for colorectal cancer and advanced adenoma detection—systematic review. United European Gastroenterology Journal, 2018, 6, 13-21.	1.6	16
193	Epigenetic and epitranscriptomic changes in colorectal cancer: Diagnostic, prognostic, and treatment implications. Cancer Letters, 2018, 419, 84-95.	3.2	52

#	ARTICLE	IF	CITATIONS
194	Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives. <i>Seminars in Cancer Biology</i> , 2018, 51, 36-49.	4.3	59
195	Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review. <i>Clinical Epigenetics</i> , 2018, 10, 35.	1.8	38
196	Updates on Translational Research on Prevention of Polyps and Colorectal Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2018, 31, 153-160.	0.5	2
197	Enrichment of methylated molecules using enhanced-ice-co-amplification at lower denaturation temperature-PCR (E-ice-COLD-PCR) for the sensitive detection of disease-related hypermethylation. <i>Epigenomics</i> , 2018, 10, 525-537.	1.0	9
198	Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study. <i>British Journal of Cancer</i> , 2018, 118, 1217-1228.	2.9	66
199	Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor. <i>International Journal of Cancer</i> , 2018, 143, 907-920.	2.3	41
200	Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies. <i>Lab on A Chip</i> , 2018, 18, 1174-1196.	3.1	234
201	Protein and glycomic plasma markers for early detection of adenoma and colon cancer. <i>Gut</i> , 2018, 67, 473-484.	6.1	61
202	Epigenetic dysregulation in adrenocortical carcinoma, a systematic review of the literature. <i>Molecular and Cellular Endocrinology</i> , 2018, 469, 77-84.	1.6	1
203	DNA Methylation Analysis of Free-Circulating DNA in Body Fluids. <i>Methods in Molecular Biology</i> , 2018, 1708, 621-641.	0.4	21
204	A Summary of the Biological Processes, Disease-Associated Changes, and Clinical Applications of DNA Methylation. <i>Methods in Molecular Biology</i> , 2018, 1708, 3-30.	0.4	32
205	Circulating tumour DNA, a promising biomarker for the management of colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 72-82.	2.0	40
206	Liquid biopsies in gastrointestinal malignancies: when is the big day?. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 19-38.	1.1	26
207	Decoding colorectal cancer epigenomics. <i>Cancer Genetics</i> , 2018, 220, 49-76.	0.2	42
208	Tumor-associated DNA mutation detection in individuals undergoing colonoscopy. <i>Cancer Medicine</i> , 2018, 7, 167-174.	1.3	12
209	Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 504-512.e11.	2.4	36
210	Circulating tumor DNA detection: A potential tool for colorectal cancer management (Review). <i>Oncology Letters</i> , 2019, 17, 1409-1416.	0.8	38
211	Distinct prognostic value of dynactin subunit 4 (DCTN4) and diagnostic value of DCTN1, DCTN2, and DCTN4 in colon adenocarcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 5807-5824.	0.9	17

#	ARTICLE	IF	CITATIONS
213	The quantitative profiling of blood <i>SEPT9</i> determines the detection performance on colorectal tumors. <i>Epigenomics</i> , 2018, 10, 1569-1583.	1.0	19
214	Clinical Interest of Circulating Tumor DNA in Oncology. <i>Archives of Medical Research</i> , 2018, 49, 297-305.	1.5	8
215	Blood free-circulating DNA testing by highly sensitive methylation assay to diagnose colorectal neoplasias. <i>Oncotarget</i> , 2018, 9, 16974-16987.	0.8	24
216	What Is the Future of Circulating Tumor Cells in Colorectal Cancer?. <i>Current Colorectal Cancer Reports</i> , 2018, 14, 207-216.	1.0	0
217	Blood-based DNA Methylation Biomarkers for Early Detection of Colorectal Cancer. <i>Journal of Proteomics and Bioinformatics</i> , 2018, 11, 120-126.	0.4	35
218	Faecal Occult Blood Point-of-Care Tests. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 402-405.	0.6	18
219	Cancers du cÅ1on : prise en charge molÃ©culaire. <i>Revue Francophone Des Laboratoires</i> , 2018, 2018, 40-45.	0.0	1
220	Circulating Tumor Cells and Circulating Tumor DNA. , 2018, , 235-281.		8
221	Genome wide DNA differential methylation regions in colorectal cancer patients in relation to blood related family members, obese and non-obese controls - a preliminary report. <i>Oncotarget</i> , 2018, 9, 25557-25571.	0.8	3
222	Recent advances in colorectal cancer screening. <i>Chronic Diseases and Translational Medicine</i> , 2018, 4, 139-147.	0.9	18
223	Biomarker discovery study of inflammatory proteins for colorectal cancer early detection demonstrated importance of screening setting validation. <i>Journal of Clinical Epidemiology</i> , 2018, 104, 24-34.	2.4	10
224	Detection of Gastric Cancer with Novel Methylated DNA Markers: Discovery, Tissue Validation, and Pilot Testing in Plasma. <i>Clinical Cancer Research</i> , 2018, 24, 5724-5734.	3.2	43
225	Early detection of ulcerative colitis-associated colorectal cancer. <i>Gastroenterology Report</i> , 2018, 6, 83-92.	0.6	35
226	Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 250-281.	157.7	1,287
227	Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer. <i>Disease Markers</i> , 2018, 2018, 1-11.	0.6	54
228	Epigenetic Epidemiology for Cancer Risk. , 2018, , 195-222.		2
229	Circulating tumour DNA for monitoring colorectal cancer—a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection. <i>Clinical Epigenetics</i> , 2018, 10, 63.	1.8	46
230	Circulating cell-free DNA as a biomarker in the diagnosis and prognosis of colorectal cancer. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 2018, 54, .	1.2	2

#	ARTICLE	IF	CITATIONS
231	Diagnostic Value of Methylated Septin9 for Colorectal Cancer Detection. <i>Frontiers in Oncology</i> , 2018, 8, 247.	1.3	46
232	The blood mSEPT9 is capable of assessing the surgical therapeutic effect and the prognosis of colorectal cancer. <i>Biomarkers in Medicine</i> , 2018, 12, 961-973.	0.6	27
233	Liquid Biopsy in Oral Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1704.	1.8	75
234	Fluorescence enhancement of silver nanocluster at intrastrand of a 12C-loop in presence of methylated region of sept 9 promoter. <i>Analytica Chimica Acta</i> , 2018, 1038, 157-165.	2.6	19
236	Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-21.	0.7	60
237	2017 Emily Couric Memorial Lecture: Colorectal Cancer: Polyps, Prevention, and Progress. <i>American Journal of Gastroenterology</i> , 2018, 113, 1772-1777.	0.2	3
238	The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. <i>Cancer Treatment Reviews</i> , 2018, 70, 1-8.	3.4	116
239	Update on the types and usage of liquid biopsies in the clinical setting: a systematic review. <i>BMC Cancer</i> , 2018, 18, 527.	1.1	76
240	A novel DNA methylation panel accurately detects colorectal cancer independently of molecular pathway. <i>Journal of Translational Medicine</i> , 2018, 16, 45.	1.8	39
241	Evaluation of bisulfite kits for DNA methylation profiling in terms of DNA fragmentation and DNA recovery using digital PCR. <i>PLoS ONE</i> , 2018, 13, e0199091.	1.1	62
242	Clinical biomarkers for cancer recognition and prevention: A novel approach with optical measurements. <i>Cancer Biomarkers</i> , 2018, 22, 179-198.	0.8	2
243	Colorectal Cancer Screening and Surveillance. , 2019, , 392-401.e3.		2
244	Epigenetics: Analysis of Cytosine Modifications at Single Base Resolution. , 2019, , 341-353.		1
245	Multiplex methylated DNA testing in plasma with high sensitivity and specificity for colorectal cancer screening. <i>Cancer Medicine</i> , 2019, 8, 5619-5628.	1.3	58
246	Next-generation sequencing in liquid biopsy: cancer screening and early detection. <i>Human Genomics</i> , 2019, 13, 34.	1.4	302
247	Epigenetic IVD Tests for Personalized Precision Medicine in Cancer. <i>Frontiers in Genetics</i> , 2019, 10, 621.	1.1	71
248	Methylated Septin 9 and Carcinoembryonic Antigen for Serological Diagnosis and Monitoring of Patients with Colorectal Cancer After Surgery. <i>Scientific Reports</i> , 2019, 9, 10326.	1.6	21
249	Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseases. <i>Nature Communications</i> , 2019, 10, 3256.	5.8	52

#	ARTICLE	IF	CITATIONS
250	High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Frontiers in Oncology</i> , 2019, 9, 622.	1.3	22
251	Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 358-367.	1.2	13
252	Hypermethylation of the SEPT9 Gene Suggests Significantly Poor Prognosis in Cancer Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Genetics</i> , 2019, 10, 887.	1.1	10
253	Cell free circulating tumor nucleic acids, a revolution in personalized cancer medicine. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 144, 102827.	2.0	22
254	Use of circulating nucleic acids, metabolites, and proteins as clinical biomarkers for earlier prognosis and diagnosis of disease. , 2019, , 85-116.		2
255	DNA Methylation Cancer Biomarkers: Translation to the Clinic. <i>Frontiers in Genetics</i> , 2019, 10, 1150.	1.1	301
256	Colorectal cancer. <i>Lancet</i> , The, 2019, 394, 1467-1480.	6.3	2,462
257	A novel panel of stool-based DNA biomarkers for early screening of colorectal neoplasms in a Chinese population. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2423-2432.	1.2	21
258	Tumor-induced DNA methylation in the white blood cells of patients with colorectal cancer. <i>Oncology Letters</i> , 2019, 18, 3039-3048.	0.8	14
260	Diagnostic Value and Clinical Significance of Methylated SEPT9 for Colorectal Cancer: A Meta-Analysis. <i>Medical Science Monitor</i> , 2019, 25, 5813-5822.	0.5	14
261	Prognosticators of Long-Term Outcomes of TNM Stage II Colorectal Cancer: Molecular Patterns or Clinicopathological Features. <i>World Journal of Surgery</i> , 2019, 43, 3207-3215.	0.8	2
262	Evaluation and Validation of Plasma Proteins Using Two Different Protein Detection Methods for Early Detection of Colorectal Cancer. <i>Cancers</i> , 2019, 11, 1426.	1.7	27
263	Progress of colorectal cancer screening in United States: Past achievements and future challenges. <i>Preventive Medicine</i> , 2019, 120, 78-84.	1.6	24
264	Application of intercalating molecules in detection of methylated DNA in the presence of silver ions. <i>Methods and Applications in Fluorescence</i> , 2019, 7, 035005.	1.1	5
265	Circulating Tumor DNA Analysis: Clinical Implications for Colorectal Cancer Patients. A Systematic Review. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz042.	1.4	22
266	Clinical value of preoperative methylated septin 9 in Chinese colorectal cancer patients. <i>World Journal of Gastroenterology</i> , 2019, 25, 2099-2109.	1.4	26
267	NFE2L3 Inhibition Induces Cell Cycle Arrest at the G0/G1 Phase in Colorectal Cancer Cells through Downregulating CCND1 and pRb1-ser807/811. <i>Disease Markers</i> , 2019, 2019, 1-7.	0.6	11
268	Clinical validity of saliva and novel technology for cancer detection. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1872, 49-59.	3.3	80

#	ARTICLE	IF	CITATIONS
269	A Novel Blood-Based Colorectal Cancer Diagnostic Technology Using Electrical Detection of Colon Cancer Secreted Protein. <i>Advanced Science</i> , 2019, 6, 1802115.	5.6	24
270	Circulating biomarkers for early detection and clinical management of colorectal cancer. <i>Molecular Aspects of Medicine</i> , 2019, 69, 107-122.	2.7	214
271	The role of mSEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer. <i>BMC Cancer</i> , 2019, 19, 450.	1.1	82
272	Exploratory Analysis of Plasma Neurotensin as a Novel Biomarker for Early Detection of Colorectal Polyp and Cancer. <i>Hormones and Cancer</i> , 2019, 10, 128-135.	4.9	13
273	Performance of a Novel Blood-Based Early Colorectal Cancer Screening Assay in Remaining Serum after the Blood Biochemical Test. <i>Disease Markers</i> , 2019, 2019, 1-6.	0.6	19
274	Detection of Colorectal Cancer in Circulating Cell-Free DNA by Methylated CpG Tandem Amplification and Sequencing. <i>Clinical Chemistry</i> , 2019, 65, 916-926.	1.5	25
275	Current Trends in Colorectal Cancer Screening. <i>Current Colorectal Cancer Reports</i> , 2019, 15, 45-52.	1.0	3
276	Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology. <i>Journal of Clinical Medicine</i> , 2019, 8, 373.	1.0	107
277	DNA methylation signatures in mendelian developmental disorders as a diagnostic bridge between genotype and phenotype. <i>Epigenomics</i> , 2019, 11, 563-575.	1.0	42
278	Cell-free tumour <i>scp</i> DNA <i>/scp</i> testing for early detection of cancer – a potential future tool. <i>Journal of Internal Medicine</i> , 2019, 286, 118-136.	2.7	50
279	A pilot study of new promising non-coding RNA diagnostic biomarkers for early-stage colorectal cancers. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1073-1083.	1.4	46
280	Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy. <i>Cancer Communications</i> , 2019, 39, 1-9.	3.7	53
281	Novel DNA methylation biomarkers show high sensitivity and specificity for blood-based detection of colorectal cancer – a clinical biomarker discovery and validation study. <i>Clinical Epigenetics</i> , 2019, 11, 158.	1.8	83
282	Toward a holistic view of multiscale breast cancer molecular biomarkers. <i>Biomarkers in Medicine</i> , 2019, 13, 1509-1533.	0.6	2
283	Correlation Between Tumor-Specific Mutated and Methylated DNA in Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-8.	1.5	7
284	Plasma MicroRNA Signature Validation for Early Detection of Colorectal Cancer. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00003.	1.3	53
286	Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma. <i>Clinical Epigenetics</i> , 2019, 11, 161.	1.8	49
287	Current Utility and Future Applications of ctDNA in Colorectal Cancer. , 0, , .		0

#	ARTICLE	IF	CITATIONS
288	Advanced liquid biopsy technologies for circulating biomarker detection. <i>Journal of Materials Chemistry B</i> , 2019, 7, 6670-6704.	2.9	118
289	Epigenetic Characterization of Cell-Free DNA. <i>Methods in Molecular Biology</i> , 2019, 1909, 129-135.	0.4	2
291	Colorectal Cancer Screening. <i>Medical Clinics of North America</i> , 2019, 103, 111-123.	1.1	17
292	Clinical epigenetics: seizing opportunities for translation. <i>Nature Reviews Genetics</i> , 2019, 20, 109-127.	7.7	353
293	Diagnostic Assessment of septin9 DNA Methylation for Colorectal Cancer Using Blood Detection: A Meta-Analysis. <i>Pathology and Oncology Research</i> , 2019, 25, 1525-1534.	0.9	17
294	Folate and Epigenetics: Colorectal Cancer Risk and Detection. , 2019, , 61-78.		0
295	Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study. <i>Clinical Chemistry</i> , 2019, 65, 559-568.	1.5	17
296	Measurement of the IgM and IgG Autoantibody Immune Responses in Human Serum has High Predictive Value for the Presence of Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, e53-e60.	1.0	15
297	Epigenomic biomarkers for prognostication and diagnosis of gastrointestinal cancers. <i>Seminars in Cancer Biology</i> , 2019, 55, 90-105.	4.3	19
298	Detection of incipient tumours by screening of circulating plasma DNA: hype or hope?. <i>Acta Clinica Belgica</i> , 2020, 75, 9-18.	0.5	9
299	Strategies for Colorectal Cancer Screening. <i>Gastroenterology</i> , 2020, 158, 418-432.	0.6	343
300	Pathways of Colorectal Carcinogenesis. <i>Gastroenterology</i> , 2020, 158, 291-302.	0.6	241
301	Colorectal carcinoma screening: Established methods and emerging technology. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 22-36.	2.7	10
302	DNA methylation and gene expression profiles characterize epigenetic regulation of lncRNAs in colon adenocarcinoma. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 2406-2415.	1.2	18
303	Multiplex screening of 275 plasma protein biomarkers to identify a signature for early detection of colorectal cancer. <i>Molecular Oncology</i> , 2020, 14, 8-21.	2.1	23
304	Endonuclease-assisted hydrogel bead array for digital analysis of circulating tumor DNA methylation. <i>Sensors and Actuators B: Chemical</i> , 2020, 304, 127381.	4.0	7
305	Tissue and Cell-Free DNA-Based Epigenomic Approaches for Cancer Detection. <i>Clinical Chemistry</i> , 2020, 66, 105-116.	1.5	26
306	Genome-wide analysis of DNA methylation identifies two CpG sites for the early screening of colorectal cancer. <i>Epigenomics</i> , 2020, 12, 37-52.	1.0	10

#	ARTICLE	IF	CITATIONS
307	Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	260
308	Circulating Extracellular Vesicle MicroRNA as Diagnostic Biomarkers in Early Colorectal Cancer—A Review. <i>Cancers</i> , 2020, 12, 52.	1.7	55
309	Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC). <i>Diagnostics</i> , 2020, 10, 9.	1.3	24
310	Screening for Colon Cancer in Older Adults: Risks, Benefits, and When to Stop. <i>Mayo Clinic Proceedings</i> , 2020, 95, 184-196.	1.4	32
311	Epigenetics of colorectal cancer: biomarker and therapeutic potential. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 111-130.	8.2	449
313	Blood-derived molecular signatures as biomarker panels for the early detection of colorectal cancer. <i>Molecular Biology Reports</i> , 2020, 47, 8159-8168.	1.0	12
314	Blood Cell DNA Methylation of Aging-Related Ubiquitination Gene DZIP3 Can Predict the Onset of Early Stage Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 544330.	1.3	7
316	Noninvasive Diagnostics for Early Detection of Lung Cancer: Challenges and Potential with a Focus on Changes in DNA Methylation. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2416-2422.	1.1	17
317	A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and Serum Biomarker for Early Stage Lung Cancer. <i>Cancer Control</i> , 2020, 27, 107327482096970.	0.7	9
318	Identification and Comprehensive Validation of a DNA Methylation-Driven Gene-Based Prognostic Model for Clear Cell Renal Cell Carcinoma. <i>DNA and Cell Biology</i> , 2020, 39, 1799-1812.	0.9	11
319	An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1125-1137.	1.3	7
320	Circulating Tumour DNAs and Non-Coding RNAs as Liquid Biopsies for the Management of Colorectal Cancer Patients. <i>Gastrointestinal Disorders</i> , 2020, 2, 212-235.	0.4	7
321	<p>Early Detection and Recurrence of Colorectal Adenomas by Combination of Eight Cancer-Associated Biomarkers in Plasma</p>. <i>Clinical and Experimental Gastroenterology</i> , 2020, Volume 13, 273-284.	1.0	4
323	Opportunistic screening and survival prediction of digestive cancers by the combination of blood <i>mSEPT9</i> with protein markers. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096296.	1.4	16
325	Treatment Response Monitoring in Patients with Advanced Malignancies Using Cell-Free SHOX2 and SEPT9 DNA Methylation in Blood. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 920-933.	1.2	15
326	The Utility of Liquid Biopsies in Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 873-886.	0.4	14
327	Hypermethylation and decreased expression of TMEM240 are potential early-onset biomarkers for colorectal cancer detection, poor prognosis, and early recurrence prediction. <i>Clinical Epigenetics</i> , 2020, 12, 67.	1.8	12
328	Liquid Biopsy in Colorectal Carcinoma: Clinical Applications and Challenges. <i>Cancers</i> , 2020, 12, 1376.	1.7	23

#	ARTICLE	IF	CITATIONS
329	Enhanced Performance of DNA Methylation Markers by Simultaneous Measurement of Sense and Antisense DNA Strands after Cytosine Conversion. <i>Clinical Chemistry</i> , 2020, 66, 925-933.	1.5	12
330	Identifying potential DNA methylation markers in early-stage colorectal Cancer. <i>Genomics</i> , 2020, 112, 3365-3373.	1.3	20
331	A novel sensitive detection method for DNA methylation in circulating free DNA of pancreatic cancer. <i>PLoS ONE</i> , 2020, 15, e0233782.	1.1	21
332	Detection of Colorectal Cancer and Advanced Adenoma by Liquid Biopsy (Decalib Study): The ddPCR Challenge. <i>Cancers</i> , 2020, 12, 1482.	1.7	16
333	CpG methylation signature defines human temporal lobe epilepsy and predicts drug-resistant. <i>CNS Neuroscience and Therapeutics</i> , 2020, 26, 1021-1030.	1.9	10
334	Epi proColon [®] for Colorectal Cancer Screening: A Profile of Its Use in the USA. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 497-503.	1.6	16
335	Stool-Based Tests for Colorectal Cancer Screening: Performance Benchmarks Lead to High Expected Efficacy. <i>Current Gastroenterology Reports</i> , 2020, 22, 32.	1.1	14
336	Serum SYPL1 is a promising diagnostic biomarker for colorectal cancer. <i>Clinica Chimica Acta</i> , 2020, 509, 36-42.	0.5	12
337	Development and Validation of a Prognostic Nomogram for Gastric Cancer Based on DNA Methylation-Driven Differentially Expressed Genes. <i>International Journal of Biological Sciences</i> , 2020, 16, 1153-1165.	2.6	45
338	DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types. <i>Cells</i> , 2020, 9, 624.	1.8	108
339	Circulating tumor DNA and liquid biopsy in oncology. <i>Nature Cancer</i> , 2020, 1, 276-290.	5.7	309
341	Aberrant DNA Methylation of SEPT9 and SDC2 in Stool Specimens as an Integrated Biomarker for Colorectal Cancer Early Detection. <i>Frontiers in Genetics</i> , 2020, 11, 643.	1.1	38
342	Value of Serum NEUROG1 Methylation for the Detection of Advanced Adenomas and Colorectal Cancer. <i>Diagnostics</i> , 2020, 10, 437.	1.3	7
343	What Is Organized Screening and What Is Its Value?. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2020, 30, 393-411.	0.6	15
344	Current status of development of methylation biomarkers for in vitro diagnostic IVD applications. <i>Clinical Epigenetics</i> , 2020, 12, 100.	1.8	44
345	Emerging Precision Oncology Applications of Liquid Biopsy using Circulating Tumour DNA and Methyome Profiling. <i>Clinical Oncology</i> , 2020, 32, 626-631.	0.6	1
346	Cost-Effectiveness of Current Colorectal Cancer Screening Tests. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2020, 30, 479-497.	0.6	10
347	Diagnostic performance of various liquid biopsy methods in detecting colorectal cancer: A meta-analysis. <i>Cancer Medicine</i> , 2020, 9, 5699-5707.	1.3	8

#	ARTICLE	IF	CITATIONS
348	Current applications and challenges of circulating tumor DNA (ctDNA) in squamous cell carcinoma of the head and neck (SCCHN). <i>Cancer Treatment Reviews</i> , 2020, 85, 101992.	3.4	17
349	Serum PIWI-Interacting RNAs piR-020619 and piR-020450 Are Promising Novel Biomarkers for Early Detection of Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 990-998.	1.1	31
350	Colorectal cancer-screening program improves both short- and long-term outcomes: a single-center experience in Trieste. <i>Updates in Surgery</i> , 2020, 72, 89-96.	0.9	8
351	Multiplex quantitation of 270 plasma protein markers to identify a signature for early detection of colorectal cancer. <i>European Journal of Cancer</i> , 2020, 127, 30-40.	1.3	19
352	Emerging Designs of Electronic Devices in Biomedicine. <i>Micromachines</i> , 2020, 11, 123.	1.4	14
353	Utility of the methylated SEPT9 test for the early detection of colorectal cancer: a systematic review and meta-analysis of diagnostic test accuracy. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000355.	1.1	28
354	Performance Comparison Between Plasma and Stool Methylated SEPT9 Tests for Detecting Colorectal Cancer. <i>Frontiers in Genetics</i> , 2020, 11, 324.	1.1	19
355	Genome-wide DNA methylation profiles of low- and high-grade adenoma reveals potential biomarkers for early detection of colorectal carcinoma. <i>Clinical Epigenetics</i> , 2020, 12, 56.	1.8	33
356	Biomarkers for Early Detection of Colorectal Cancer: The Early Detection Research Network, a Framework for Clinical Translation. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2431-2440.	1.1	23
357	Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests. <i>Journal of the National Cancer Institute</i> , 2021, 113, 154-161.	3.0	46
358	The Application of Circulating Tumor DNA in the Screening, Surveillance, and Treatment Monitoring of Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 1845-1858.	0.7	5
359	DNA methylation markers detected in blood, stool, urine, and tissue in colorectal cancer: a systematic review of paired samples. <i>International Journal of Colorectal Disease</i> , 2021, 36, 239-251.	1.0	25
360	Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence. <i>Clinical Cancer Research</i> , 2021, 27, 141-149.	3.2	17
361	Epigenetic Alterations in the Gastrointestinal Tract: Current and Emerging Use for Biomarkers of Cancer. <i>Gastroenterology</i> , 2021, 160, 690-709.	0.6	112
363	Evaluating a New Cancer Screening Blood Test: Unintended Consequences and the Need for Clarity in Policy Making. <i>Journal of the National Cancer Institute</i> , 2021, 113, 109-111.	3.0	4
364	The DNA methylation landscape of <i>PD-1</i> (<i>PDCD1</i>) and adjacent lncRNA <i>AC131097.3</i> in head and neck squamous cell carcinoma. <i>Epigenomics</i> , 2021, 13, 113-127.	1.0	9
365	Evaluation of a panel of tumor-specific differentially-methylated DNA regions in <i>IRF4</i> , <i>IKZF1</i> and <i>BCAT1</i> for blood-based detection of colorectal cancer. <i>Clinical Epigenetics</i> , 2021, 13, 14.	1.8	14
366	Principles of epigenetics and DNA methylation. , 2021, , 3-26.		0

#	ARTICLE	IF	CITATIONS
367	A site-specific DNA methylation biosensor for both visual and magnetic determination based on lateral flow assay. <i>Analyst</i> , The, 2021, 146, 2248-2254.	1.7	3
368	Comparison of Proteomic Technologies for Blood-Based Detection of Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1189.	1.8	6
369	Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy. <i>Advances in Cancer Research</i> , 2021, 151, 231-304.	1.9	8
370	Blood leukocytes methylation levels analysis indicate methylated plasma test is a promising tool for colorectal cancer early detection. <i>Journal of Cancer</i> , 2021, 12, 3678-3685.	1.2	12
371	Methylated <i>SFRP2</i> and <i>SDC2</i> in stool specimens for Colorectal Cancer early detection: A cost-effective strategy for Chinese population. <i>Journal of Cancer</i> , 2021, 12, 2665-2672.	1.2	13
372	Discovery and validation of methylation signatures in blood-based circulating tumor cell-free DNA in early detection of colorectal carcinoma: a case-control study. <i>Clinical Epigenetics</i> , 2021, 13, 26.	1.8	19
373	Colorectal cancer screening and diagnosis: omics-based technologies for development of a non-invasive blood-based method. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 723-738.	1.1	9
374	Epigenetic Landscape of Liquid Biopsy in Colorectal Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 622459.	1.8	31
375	Two novel qualitative transcriptional signatures robustly applicable to non-research-oriented colorectal cancer samples with low-quality RNA. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 3622-3633.	1.6	5
376	ACG Clinical Guidelines: Colorectal Cancer Screening 2021. <i>American Journal of Gastroenterology</i> , 2021, 116, 458-479.	0.2	351
377	A novel cell-free DNA methylation-based model improves the early detection of colorectal cancer. <i>Molecular Oncology</i> , 2021, 15, 2702-2714.	2.1	29
378	Identifying Novel Biomarkers Ready for Evaluation in Low-Prevalence Populations for the Early Detection of Lower Gastrointestinal Cancers: A Systematic Review and Meta-Analysis. <i>Advances in Therapy</i> , 2021, 38, 3032-3065.	1.3	3
379	Model-Based Estimation of Colorectal Cancer Screening and Outcomes During the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2021, 4, e216454.	2.8	32
380	Values of liquid biopsy in early detection of cancer: results from meta-analysis. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 417-427.	1.5	5
381	Screening for Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1978.	3.8	219
382	Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. <i>Trends in Molecular Medicine</i> , 2021, 27, 482-500.	3.5	128
383	The pan-cancer noninvasive screening and early detection by epigenetic techniques. <i>Epigenomics</i> , 2021, 13, 649-652.	1.0	1
384	Prognostic biomarker identification and tumor classification in breast cancer patients by methylation and transcriptome analysis. <i>FEBS Open Bio</i> , 2021, 11, 2139-2151.	1.0	5

#	ARTICLE	IF	CITATIONS
385	Value of methylation markers in colorectal cancer (Review). <i>Oncology Reports</i> , 2021, 46, .	1.2	8
386	Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies. <i>Cancers</i> , 2021, 13, 3016.	1.7	38
387	A Pilot Study Investigating the Expression Levels of Pluripotency-Associated Genes in Rectal Swab Samples for Colorectal Polyp and Cancer Diagnosis and Prognosis. <i>Stem Cells International</i> , 2021, 2021, 1-17.	1.2	2
388	Circulating tumor DNA in cancer: Predictive molecular pathology meets mathematics. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103394.	2.0	7
389	Methylation profile of colon cancer genes in colorectal precursor lesions and tumor tissue: perspectives for screening. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 920-928.	0.6	9
390	Narrative review of the influence of diabetes mellitus and hyperglycemia on colorectal cancer risk and oncological outcomes. <i>Translational Oncology</i> , 2021, 14, 101089.	1.7	37
391	Upregulation of circular and linear METTL3 and USP3 in colorectal cancer. <i>Oncology Letters</i> , 2021, 22, 675.	0.8	3
392	Fecal Bacteria as Non-Invasive Biomarkers for Colorectal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 664321.	1.3	17
393	Advances in colorectal cancer genomics and transcriptomics drive early detection and prevention. <i>International Journal of Biochemistry and Cell Biology</i> , 2021, 137, 106032.	1.2	5
394	Detection of Circulating Tumor DNA Methylation in Diagnosis of Colorectal Cancer. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00386.	1.3	10
395	Evaluation of a 92 multiplex protein panel in detection of colorectal cancer and high-risk adenoma in 784 symptomatic individuals. <i>Cancer Biomarkers</i> , 2021, 32, 73-84.	0.8	2
396	Risk-Predictive and Diagnostic Biomarkers for Colorectal Cancer; a Systematic Review of Studies Using Pre-Diagnostic Blood Samples Collected in Prospective Cohorts and Screening Settings. <i>Cancers</i> , 2021, 13, 4406.	1.7	14
397	Screening and prevention of colorectal cancer. <i>BMJ</i> , The, 2021, 374, n1855.	3.0	141
398	Exploration of the Proteomic Landscape of Small Extracellular Vesicles in Serum as Biomarkers for Early Detection of Colorectal Neoplasia. <i>Frontiers in Oncology</i> , 2021, 11, 732743.	1.3	7
399	Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 1165-1178.	1.5	20
400	Role of blood mSEPT9 in evaluating tumor burden and disease monitoring in colorectal cancer patients. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e24030.	0.9	4
401	Low Prevalence of Screen-Detected Colorectal Cancer in an Average-Risk Population: The New Normal. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2650-2652.e1.	2.4	3
402	mSEPT9 Can Monitor the Response and Predict the Prognosis of Stage IV Colorectal Cancer Patients with Liver Metastasis Undergoing Potentially Curative Surgery. <i>Journal of Surgical Research</i> , 2021, 267, 485-494.	0.8	3

#	ARTICLE	IF	CITATIONS
403	Field carcinogenesis for risk stratification of colorectal cancer. <i>Advances in Cancer Research</i> , 2021, 151, 305-344.	1.9	6
404	Biomarkers as Putative Therapeutic Targets in Colorectal Cancer. , 2021, , 123-177.		0
405	KCNQ5 and C9orf50 Methylation in Stool DNA for Early Detection of Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 621295.	1.3	12
406	A Qualitative Transcriptional Signature for the Risk Assessment of Precancerous Colorectal Lesions. <i>Frontiers in Genetics</i> , 2020, 11, 573787.	1.1	5
407	Epigenetic alterations in the gastrointestinal tract: Current and emerging use for biomarkers of cancer. <i>Advances in Cancer Research</i> , 2021, 151, 425-468.	1.9	20
408	Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	51
409	Epigenetics of Colorectal Cancer. <i>Methods in Molecular Biology</i> , 2015, 1238, 405-424.	0.4	17
410	Cancer Methylation Biomarkers in Circulating Cell-Free DNA. , 2019, , 217-245.		3
411	Application of Multiplex Bisulfite PCRâ€“Ligase Detection Reactionâ€“Real-Time Quantitative PCR Assay in Interrogating Bioinformatically Identified, Blood-Based Methylation Markers for Colorectal Cancer. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 885-900.	1.2	5
412	5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers. <i>Cell Research</i> , 2017, 27, 1243-1257.	5.7	262
413	Noninvasive strategies for colorectal cancer screening: opportunities and limitations. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 44-51.	1.0	9
415	Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. <i>Gut</i> , 2018, 67, 1995-2005.	6.1	188
416	Non-Invasive Colorectal Cancer Screening: An Overview. <i>Gastrointestinal Tumors</i> , 2020, 7, 62-73.	0.3	62
417	CTLA4 methylation predicts response to antiâ€“PD-1 and antiâ€“CTLA-4 immunotherapy in melanoma patients. <i>JCI Insight</i> , 2018, 3, .	2.3	67
418	Tumor circulome in the liquid biopsies for digestive tract cancer diagnosis and prognosis. <i>World Journal of Clinical Cases</i> , 2020, 8, 2066-2080.	0.3	5
419	Current state and future direction of screening tool for colorectal cancer. <i>World Journal of Meta-analysis</i> , 2019, 7, 184-208.	0.1	1
420	Detection of Methylated Septin 9 in Tissue and Plasma of Colorectal Patients with Neoplasia and the Relationship to the Amount of Circulating Cell-Free DNA. <i>PLoS ONE</i> , 2014, 9, e115415.	1.1	87
421	Diagnostic Performance of DNA Hypermethylation Markers in Peripheral Blood for the Detection of Colorectal Cancer: A Meta-Analysis and Systematic Review. <i>PLoS ONE</i> , 2016, 11, e0155095.	1.1	20

#	ARTICLE	IF	CITATIONS
422	Algorithm Optimization in Methylation Detection with Multiple RT-qPCR. PLoS ONE, 2016, 11, e0163333.	1.1	26
423	Colorectal cancer, screening: achievements and opportunities. Onkologija i Koloproktologija, 2018, 8, 11-29.	0.1	6
424	Identifying CpG methylation signature as a promising biomarker for recurrence and immunotherapy in non-small-cell lung carcinoma. Aging, 2020, 12, 14649-14676.	1.4	17
425	LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer. Oncotarget, 2017, 8, 11906-11916.	0.8	64
426	Non-blood circulating tumor DNA detection in cancer. Oncotarget, 2017, 8, 69162-69173.	0.8	93
427	Circulating cell-free nucleosomes as biomarkers for early detection of colorectal cancer. Oncotarget, 2018, 9, 10247-10258.	0.8	24
428	Hypermethylation of <i>BEND5</i> contributes to cell proliferation and is a prognostic marker of colorectal cancer. Oncotarget, 2017, 8, 113431-113443.	0.8	12
429	Identification and validation of colorectal neoplasia-specific methylation biomarkers based on CTCF-binding sites. Oncotarget, 2017, 8, 114183-114194.	0.8	3
430	Deregulation of methylation of transcribed-ultra conserved regions in colorectal cancer and their value for detection of adenomas and adenocarcinomas. Oncotarget, 2018, 9, 21411-21428.	0.8	10
431	Tumor circulating DNA profiling in xenografted mice exposed to intermittent hypoxia. Oncotarget, 2015, 6, 556-569.	0.8	34
432	Circulating molecular biomarkers for screening or early diagnosis of colorectal cancer: which is ready for prime time?. Annals of Translational Medicine, 2019, 7, 610-610.	0.7	35
433	Blood-Based Detection of Colorectal Cancer Using Cancer-Specific DNA Methylation Markers. Diagnostics, 2021, 11, 51.	1.3	11
434	Plasma levels of methylated septin 9 are capable of detecting hepatocellular carcinoma and hepatic cirrhosis. Molecular Medicine Reports, 2020, 22, 2705-2714.	1.1	5
435	Cell-free DNA as a liquid biopsy for early detection of gastric cancer (Review). Oncology Letters, 2020, 21, 1-1.	0.8	18
436	"Liquid biopsy"-ctDNA detection with great potential and challenges. Annals of Translational Medicine, 2015, 3, 235.	0.7	77
437	Colorectal cancer screening guidelines for Nigeria in 2019. Nigerian Journal of Gastroenterology and Hepatology, 2019, 11, 42.	0.2	4
438	Advance in plasma SEPT9 gene methylation assay for colorectal cancer early detection. World Journal of Gastrointestinal Oncology, 2018, 10, 15-22.	0.8	48
439	Current noninvasive tests for colorectal cancer screening: An overview of colorectal cancer screening tests. World Journal of Gastrointestinal Oncology, 2016, 8, 793.	0.8	77

#	ARTICLE	IF	CITATIONS
440	<i>Syndecan-2</i> Methylation as a New Biomarker for Early Detection of Colorectal Neoplasm. Gut and Liver, 2018, 12, 479-480.	1.4	6
441	Recognition of DNA Methylation Molecular Features for Diagnosis and Prognosis in Gastric Cancer. Frontiers in Genetics, 2021, 12, 758926.	1.1	6
443	A combination of methylation and protein markers is capable of detecting gastric cancer detection by combined markers. Epigenomics, 2021, 13, 1557-1570.	1.0	13
444	Current Screening and Surveillance Guidelines. , 2015, , 13-43.		1
445	The Epigenetics in Intestinal Tumorigenesis. , 2015, , 137-168.		0
447	Folate and Epigenetics: Colorectal Cancer Risk and Detection. , 2017, , 1-19.		1
448	Occult blood fecal tests for self-control and point of care testing. Diagnostyka Laboratoryjna I WiadomoÅci PTDL, 2017, 53, 101-106.	0.0	0
449	Circulating Molecular and Cellular Biomarkers in Cancer. , 0, , 607-656.		1
450	Estado actual de las aplicaciones del ADN libre de cÅ©lula circulante. Medicina Y Laboratorio, 2017, 23, 551-564.	0.0	0
451	Liquid biopsies in myeloid malignancies. , 2019, 2, 1044-1061.		5
452	CpG Islands Methylation Alterations in Cancer: Functionally Intriguing Security Locks, Useful Early Tumor Biomarkers. RNA Technologies, 2019, , 53-62.	0.2	0
453	Colorectal Cancer Prevention. , 2019, , 473-509.		1
455	Diagnostic accuracy of m2 pyruvate kinase quick stool test and fecal occult blood test for detection of colorectal cancer. Medical Journal of Tabriz University of Medical Sciences & Health Services, 2020, 42, 287-294.	0.1	0
456	Targeted Bisulfite Sequencing Reveals DNA Methylation Changes in Zinc Finger Family Genes Associated With KRAS Mutated Colorectal Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 759813.	1.8	7
457	DNA methylation biomarkers in peripheral blood of patients with head and neck squamous cell carcinomas. A systematic review. PLoS ONE, 2020, 15, e0244101.	1.1	8
458	The Role of DNA Methylation in Cancer. , 2020, , 491-511.		0
459	Labordiagnostik/Tumormarker: Was ist sinnvoll/effektiv, was wird kommen?. , 2020, , 191-207.		0
461	Cancer Epigenomics and Beyond: Advancing the Precision Oncology Paradigm. Journal of Immunotherapy and Precision Oncology, 2020, 3, 147-156.	0.6	0

#	ARTICLE	IF	CITATIONS
462	Options of Colorectal Cancer Screening: An Overview. , 2021, , 29-40.		0
463	Noninvasive Screening Test. , 2021, , 55-65.		0
464	Tests detecting biomarkers for screening of colorectal cancer: What is on the horizon?. GMS Health Technology Assessment, 2015, 11, Doc01.	2.2	2
465	Serrated Polyps in the Colon. Gastroenterology and Hepatology, 2014, 10, 671-4.	0.2	3
466	Epigenetics in diagnosis of colorectal cancer. Molecular Biology Research Communications, 2016, 5, 49-57.	0.2	14
468	Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based Testing. American Health and Drug Benefits, 2019, 12, 256-262.	0.5	7
469	Diagnostic and prognostic values of forkhead box D4 gene in colonic adenocarcinoma. International Journal of Clinical and Experimental Pathology, 2020, 13, 2615-2627.	0.5	0
470	Screening and diagnosis of colorectal cancer and advanced adenoma by Bionic Glycome method and machine learning. American Journal of Cancer Research, 2021, 11, 3002-3020.	1.4	4
471	Translational epigenetics in precision medicine of colorectal cancer. , 2022, , 19-41.		0
472	Perspectives and future directions of translational epigenetics in personalized and precision medicine. , 2022, , 1-18.		0
473	Methylated circulating tumor DNA biomarkers for the blood-based detection of cancer signals. , 2022, , 471-512.		0
474	The Evaluation of Methylated Septin 9 in Blood Plasma and Tissue Biopsies for the Early Detection for Asymptomatic Colon Cancer. Open Access Macedonian Journal of Medical Sciences, 2020, 9, 1462-1469.	0.1	0
475	Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer. Cancers, 2021, 13, 5615.	1.7	20
476	Screening for Colorectal Cancer Leading into a New Decade: The "Roaring" for Epigenetic Biomarkers?. Current Oncology, 2021, 28, 4874-4893.	0.9	9
477	Non-coding RNAs as liquid biopsy biomarkers in cancer. British Journal of Cancer, 2022, 126, 351-360.	2.9	44
478	The Role of Small Extracellular Vesicles in the Progression of Colorectal Cancer and Its Clinical Applications. International Journal of Molecular Sciences, 2022, 23, 1379.	1.8	8
479	A risk scoring system to predict the individual incidence of early-onset colorectal cancer. BMC Cancer, 2022, 22, 122.	1.1	9
480	AGA Clinical Practice Update on Approach to the Use of Noninvasive Colorectal Cancer Screening Options: Commentary. Gastroenterology, 2022, 162, 952-956.	0.6	5

#	ARTICLE	IF	CITATIONS
481	Noninvasive Detection of Esophageal Cancer by the Combination of mSEPT9 and SNCG. Genetic Testing and Molecular Biomarkers, 2022, 26, 8-16.	0.3	1
482	Tumor-Informed Versus Plasma-Only Liquid Biopsy Assay in a Patient With Multiple Primary Malignancies. JCO Precision Oncology, 2022, 6, e2100298.	1.5	6
483	Novel Diagnostic Biomarkers in Colorectal Cancer. International Journal of Molecular Sciences, 2022, 23, 852.	1.8	75
484	Genome-Wide Methylation Profiling of lncRNAs Reveals a Novel Progression-Related and Prognostic Marker for Colorectal Cancer. Frontiers in Oncology, 2021, 11, 782077.	1.3	3
485	Isolation and Quantification of Methylated Cell-Free DNA in Plasma on an Integrated Microfluidic System. Analytical Chemistry, 2022, 94, 2134-2141.	3.2	3
486	Early detection of colorectal neoplasia: application of a blood-based serological protein test on subjects undergoing population-based screening. British Journal of Cancer, 2022, , .	2.9	4
487	Uncovering potential genes in colorectal cancer based on integrated and DNA methylation analysis in the gene expression omnibus database. BMC Cancer, 2022, 22, 138.	1.1	6
488	Methylated Septin9 (<i>mSEPT9</i>): A Promising Blood-Based Biomarker for the Detection and Screening of Early-Onset Colorectal Cancer. Cancer Research Communications, 2022, 2, 90-98.	0.7	8
489	A DNA-Methylation-Driven Genes Based Prognostic Signature Reveals Immune Microenvironment in Pancreatic Cancer. Frontiers in Immunology, 2022, 13, 803962.	2.2	13
491	HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples. British Journal of Cancer, 2022, 126, 1783-1794.	2.9	12
492	Systematic review: non-€endoscopic surveillance for colorectal neoplasia in individuals with Lynch syndrome. Alimentary Pharmacology and Therapeutics, 2022, 55, 778-788.	1.9	6
493	Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. Molecular Cancer, 2022, 21, 86.	7.9	72
494	Colorectal cancer screening preferences among physicians and individuals at average risk: A discrete choice experiment. Cancer Medicine, 2022, 11, 3156-3167.	1.3	4
495	Plasma Extracellular Vesicle Long RNAs Have Potential as Biomarkers in Early Detection of Colorectal Cancer. Frontiers in Oncology, 2022, 12, 829230.	1.3	0
496	Circulating tumor DNA methylation marker MYO1-G for diagnosis and monitoring of colorectal cancer. Clinical Epigenetics, 2021, 13, 232.	1.8	17
497	Genotypic and Phenotypic Characteristics of Hereditary Colorectal Cancer. Annals of Coloproctology, 2021, 37, 368-381.	0.5	14
498	Application of droplet digital polymerase chain reaction of plasma methylated septin 9 on detection and early monitoring of colorectal cancer. Scientific Reports, 2021, 11, 23446.	1.6	7
499	Methylation of FBN1, SPG20, ITF2, RUNX3, SNCA, MLH1, and SEPT9 genes in circulating cell-free DNA as biomarkers of colorectal cancer. Cancer Biomarkers, 2022, 34, 221-250.	0.8	9

#	ARTICLE	IF	CITATIONS
510	Colorectal Cancer Screening in China: Status, Challenges, and Prospects â€” China, 2022. China CDC Weekly, 2022, 4, 322-328.	1.0	16
511	Distinct Performance of Methylated <i>SEPT9</i> in Upper and Lower Gastrointestinal Cancers and Combined Detection with Protein Markers. Genetic Testing and Molecular Biomarkers, 2022, 26, 239-248.	0.3	1
512	Circulating cell-free DNA for cancer early detection. Innovation(China), 2022, 3, 100259.	5.2	35
513	Methylated Septin9 has moderate diagnostic value in colorectal cancer detection in Chinese population: a multicenter study. BMC Gastroenterology, 2022, 22, 232.	0.8	8
514	Current and future colorectal cancer screening strategies. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 521-531.	8.2	102
515	Seven DNA Methylation Biomarker Prediction Models for Monitoring the Malignant Progression From Advanced Adenoma to Colorectal Cancer. Frontiers in Oncology, 2022, 12, .	1.3	1
516	Adenosine Kinase on Deoxyribonucleic Acid Methylation: Adenosine Receptor-Independent Pathway in Cancer Therapy. Frontiers in Pharmacology, 0, 13, .	1.6	3
518	Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma. Seminars in Liver Disease, 2022, 42, 188-201.	1.8	6
519	Current and Future Perspectives of Cell-Free DNA in Liquid Biopsy. Current Issues in Molecular Biology, 2022, 44, 2695-2709.	1.0	11
520	Reducing the Burden of Colorectal Cancer: AGA Position Statements. Gastroenterology, 2022, 163, 520-526.	0.6	6
521	Future of Colorectal Cancer Screening: From One-Size-FITs-All to Tailor-Made. , 0, 1, .		4
522	Circulating cancer biomarkers: current status and future prospects. , 2022, , 409-443.		0
523	Diagnostic accuracy of DNA-based SDC2 methylation test in colorectal cancer screening: a meta-analysis. BMC Gastroenterology, 2022, 22, .	0.8	8
524	Methylated Septin 9 as a Promising Biomarker in the Diagnosis and Recurrence Monitoring of Colorectal Cancer. Disease Markers, 2022, 2022, 1-8.	0.6	9
525	The influence of blood sample processing on blood-based DNA methylation signatures. Clinical Biochemistry, 2023, 115, 116-125.	0.8	0
526	Noninvasive early detection of colorectal cancer by hypermethylation of the LINC00473 promoter in plasma cell-free DNA. Clinical Epigenetics, 2022, 14, .	1.8	8
527	Considerations of Biomarker Application for Cancer Continuum in the Era of Precision Medicine. Current Epidemiology Reports, 2022, 9, 200-211.	1.1	2
528	Epigenetic Biomarkers. , 2023, , 303-321.		0

#	ARTICLE	IF	CITATIONS
529	Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer. <i>Medical Science Monitor</i> , 0, 28, .	0.5	1
530	Early Dynamics of Quantitative SEPT9 and SHOX2 Methylation in Circulating Cell-Free Plasma DNA during Prostate Biopsy for Prostate Cancer Diagnosis. <i>Cancers</i> , 2022, 14, 4355.	1.7	4
531	Clinical presentation, management, screening and surveillance for colorectal cancer during the COVID-19 pandemic. <i>World Journal of Clinical Cases</i> , 2022, 10, 9228-9240.	0.3	4
532	A simplified multiplex methylated DNA testing for early detection of colorectal cancer in stool DNA. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	1
533	Serum <sc>IgG</sc> N-glycans enable early detection and early relapse prediction of colorectal cancer. <i>International Journal of Cancer</i> , 2023, 152, 536-547.	2.3	9
534	Biomarcadores plasmáticos : ¿nuevas pruebas no invasivas en el diagnóstico precoz de cáncer colorrectal?. <i>Horizonte Médico</i> , 2022, 22, e1977.	0.1	0
535	Epidemiology, Risk Factors, and Prevention of Colorectal Cancer-An English Version. <i>Journal of the Anus, Rectum and Colon</i> , 2022, 6, 231-238.	0.4	4
536	Genome-wide screening for differentially methylated long noncoding RNAs identifies LIFR-AS1 as an epigenetically regulated lncRNA that inhibits the progression of colorectal cancer. <i>Clinical Epigenetics</i> , 2022, 14, .	1.8	5
538	CircHADHA-augmented autophagy suppresses tumor growth of colon cancer by regulating autophagy-related gene via miR-361. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
539	Genome-wide methylation profiling identifies a novel gene signature for patients with synchronous colorectal cancer. <i>British Journal of Cancer</i> , 0, , .	2.9	1
540	Performance of circulating methylated Septin9 gene DNA in diagnosis and recurrence monitoring of colorectal cancer in Western China. <i>Clinica Chimica Acta</i> , 2022, 537, 118-126.	0.5	3
541	Blood-based DNA methylation signatures in cancer: A systematic review. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2023, 1869, 166583.	1.8	8
542	Nutrigenomics in the management and prevention of cancer. , 2023, , 177-208.		0
543	Current and Emerging Technologies for the Analysis of the Genome-Wide and Locus-Specific DNA Methylation Patterns. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 395-469.	0.8	2
544	Early detection and prognosis prediction for colorectal cancer by circulating tumour DNA methylation haplotypes: a multicentre cohort study. <i>EClinicalMedicine</i> , 2023, 55, 101717.	3.2	23
545	How ctDNA Changing the Landscape of Management of Colorectal Cancers. , 0, 1, 33-40.		0
546	Rapid and ultra-sensitive early detection of cervical cancer using CRISPR/Cas12-based assay based on methylated SEPT9. <i>Sensors and Actuators B: Chemical</i> , 2023, 379, 133231.	4.0	0
547	Emerging Tests for Noninvasive Colorectal Cancer Screening. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 604-616.	2.4	9

#	ARTICLE	IF	CITATIONS
548	Using Circulating Tumor DNA as a Novel Biomarker to Screen and Diagnose Colorectal Cancer: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2023, 12, 408.	1.0	8
549	Which technology performs better? From sample volume to extraction and molecular profiling. , 2023, , 119-202.		0
550	Liquid biopsy: a right tool in a right context?. , 2023, , 31-45.		0
551	Blood-Based Cancer Screening/Early Cancer Detection. , 2023, , 1-31.		0
553	Joint Asian Pacific Association of Gastroenterology (APAGE)â€”Asian Pacific Society of Digestive Endoscopy (APSDE) clinical practice guidelines on the use of non-invasive biomarkers for diagnosis of colorectal neoplasia. <i>Gut</i> , 2023, 72, 1240-1254.	6.1	4
554	Epigenetic reprogramming in cancer: From diagnosis to treatment. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	4
555	The Position of Circulating Tumor DNA in the Clinical Management of Colorectal Cancer. <i>Cancers</i> , 2023, 15, 1284.	1.7	5
556	Inhibitors targeting epigenetic modifications in cancer. , 2023, , 287-324.		0
557	Types of Liquid Biopsies: Understanding the Different Lenses Through Which They Can Detect Cancer. <i>Oncologist</i> , 2023, 28, 281-282.	1.9	0
558	Surveillance Colonoscopy After Polypectomyâ€”Current Evidence and Future Directions. <i>Techniques and Innovations in Gastrointestinal Endoscopy</i> , 2023, 25, 269-283.	0.4	0
559	IgG N-glycan Signatures as Potential Diagnostic and Prognostic Biomarkers. <i>Diagnostics</i> , 2023, 13, 1016.	1.3	4
560	Circulating Tumor Cells and Cell-free Nucleic Acids as Biomarkers in Colorectal Cancer. <i>Current Pharmaceutical Design</i> , 2023, 29, 748-765.	0.9	4
561	Current Applications of Liquid Biopsy in Gastrointestinal Cancer Diseaseâ€”From Early Cancer Detection to Individualized Cancer Treatment. <i>Cancers</i> , 2023, 15, 1924.	1.7	1
562	Application and development of noninvasive biomarkers for colorectal cancer screening: a systematic review. <i>International Journal of Surgery</i> , 2023, 109, 925-935.	1.1	2
563	Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation. <i>JAMA Oncology</i> , 2023, 9, 770.	3.4	15
610	Challenge of Colorectal Screening in Developing Countries. , 0, , .		0